Vilon peptide dosage figures from the published record are set out below, alongside the chemistry behind them. Vilon is a lyophilized vial of the dipeptide Lys-Glu, written KE, and at two residues it is the shortest compound in the Khavinson bioregulator range.
Specification Table
Vilon verified chemical and handling data
| Property |
Value |
| Compound |
Vilon |
| Sequence designation |
KE |
| Amino acid sequence |
Lysine-Glutamate |
| Residue count |
2 |
| Approximate molecular weight |
275.3 g/mol for the free dipeptide |
| Net charge at neutral pH |
Zwitterionic, one basic and one acidic residue |
| Oxidation-prone residues |
None |
| Compound class |
Short peptide bioregulator, cytogen subclass |
| Cytogen versus cytomax |
Cytogen. A laboratory-synthesised defined sequence, not a tissue extract |
| Source tissue of the parent fraction |
Thymus and immune tissue |
| Originating programme |
St Petersburg Institute of Bioregulation and Gerontology |
| Programme lead |
Vladimir Khavinson |
| Proposed mechanism in the literature |
Sequence-specific interaction with DNA, modulating tissue-associated gene expression |
| Mechanism status |
Hypothesis. Not independently established outside the originating programme |
| Receptor |
None identified |
| Appearance |
White lyophilized powder |
| Purity |
Per lot-specific certificate of analysis |
| Solubility |
Water soluble |
| Storage, lyophilized |
2-8°C or -20°C, protected from light and moisture |
| Regulatory status |
No approved human or veterinary formulation in any jurisdiction |
What Vilon Peptide Dosage Appears in Published Work?
Vilon peptide dosage is asked about constantly, and the question deserves actual figures rather than a deflection.
Rodent studies from the originating programme have used intraperitoneal and subcutaneous amounts spanning roughly 0.1 to 10 micrograms per kilogram, which is very low compared with most peptides in this catalogue.
Russian clinical literature describes amounts in the range of tens to low hundreds of micrograms per exposure, typically over courses of ten to twenty days rather than continuously.
Those figures come from one national research tradition and have not been replicated in Western trials. That is the caveat attached to every number in this cluster and it should travel with them.
Converting between species is not arithmetic on body weight. Allometric scaling through body surface area is the accepted method, and an unscaled rodent figure does not transfer.
The low absolute amounts are themselves worth noting. Micrograms per kilogram is two to three orders of magnitude below where most short peptides in this catalogue are studied, which is a claim about potency that the mechanism does not currently explain.
Why Is a Two-Residue Peptide Unusual?
Vilon peptide sits at the extreme end of the short-peptide idea and examining it clarifies what the whole bioregulator hypothesis requires.
A dipeptide has one peptide bond. It has essentially no conformational preference, no secondary structure, and a surface area smaller than most small-molecule drugs. There is very little of it for anything to recognise specifically.
Conventional receptor pharmacology works through complementary surfaces, and a recognition event usually needs several contact points distributed across a folded shape. Two residues cannot supply that.
The proposed mechanism in this literature sidesteps receptors entirely, suggesting instead a sequence-specific interaction with DNA that modulates transcription of tissue-associated genes.
For a dipeptide that proposal is more demanding than for a tetrapeptide, because sequence-specific DNA recognition normally requires reading several base pairs and a two-residue ligand offers minimal information content to do it with.
None of this makes the compound uninteresting. It makes it a clean test case: if the hypothesis holds anywhere, the constraints on where it can hold are tightest here.
What Does Buying Vilon Bioregulator Require Checking?
Vilon peptide is trivial to synthesise and trivial to characterise, so a thin certificate has nothing behind it at all.
Mass confirmation against roughly 275.3 for the free dipeptide. At two residues the mass spectrum is unambiguous and any competent instrument resolves it.
Purity by reversed-phase chromatography. A dipeptide retains poorly on standard reversed-phase because it is small and polar, so the method needs adapting and a supplier using a default peptide gradient may not be separating anything.
Counterion identity matters disproportionately here. At 275.3 daltons a single trifluoroacetate at 114 daltons is over 29 percent of the associated mass, which is the largest counterion correction of any compound in this catalogue.
Net peptide content follows from that and it is the figure to calculate from rather than the vial label.
Stereochemistry is worth confirming. Lys-Glu and the corresponding D-amino acid variants have identical mass, and chiral analysis or comparison against a reference standard is the only way to tell them apart.
How Should Vilon 20mg Be Handled?
Vilon peptide is among the most chemically forgiving compounds in the entire catalogue and the handling notes are correspondingly short.
Twenty milligrams at roughly 275.3 daltons is approximately 72.6 micromoles, which is an enormous molar quantity by the standards of this range and far more than most designs will consume.
No cysteine means no disulfide chemistry. No methionine or tryptophan means the fastest oxidation routes are unavailable. No asparagine-glycine motif means the quickest deamidation path is absent. There is almost nothing here for degradation chemistry to act on.
Water solubility is good, helped by the zwitterionic character. Add diluent slowly and swirl; material that resists dissolving is worth questioning rather than agitating.
Hold lyophilized material sealed against light and moisture. Refrigerated storage is sufficient and freezing is unnecessary for a compound this stable, though it does no harm.
Record lot, counterion where known, net peptide content, diluent, volume, concentration and date.
What Would a Rigorous Vilon Study Include?
Given the mechanism is unresolved, the controls carry the weight that binding data would normally carry.
A reversed-sequence control is the primary specificity test. Glu-Lys has identical composition and identical mass to Lys-Glu, differing only in order, which makes it the cleanest comparator available for any sequence-specific claim.
That control is unusually strong for a dipeptide, because with only two residues there is exactly one alternative ordering. For a tetrapeptide there are twenty-four, and a scrambled control tests only one of them.
Free amino acid arms are worth running alongside. Lysine and glutamate separately, at the same molar concentrations, distinguish an effect of the dipeptide from an effect of its constituents after hydrolysis.
For the DNA-binding proposal, direct biophysical measurement beats inference from expression. Isothermal titration calorimetry, surface plasmon resonance against immobilised oligonucleotides, or electrophoretic mobility shift assays all measure binding rather than assuming it.
Wide concentration ranging is necessary rather than thorough, because no affinity is known and no concentration can be justified from first principles.
How Do Vilon Peptide Dosage Figures Compare Across the Family?
Placing the numbers alongside the rest of the bioregulator range clarifies whether Vilon is unusual or typical.
Every compound in this family is described at amounts in the microgram per kilogram band in rodent work, which is two to three orders of magnitude below where most short peptides in this catalogue are studied.
That consistency is itself informative. It suggests the published figures derive from a shared methodology within one programme rather than from independent amount-ranging studies on each compound.
Published Vilon peptide dosage figures sit at the lower end even of that band, which the literature leaves open to two readings: a shorter peptide being more potent, or amounts chosen by convention rather than measured.
Distinguishing those two possibilities requires concentration-response data that the published record does not currently provide for any member of the family.
For a researcher the practical consequence is to take every published figure here as a starting reference rather than an established value, and to range widely around it.
Where Does Vilon Peptide For Sale Documentation Usually Fall Short?
Comparing suppliers on Vilon peptide dosage claims and documentation comes down to a short list of answerable questions.
Measured mass rather than a catalogue figure. For a dipeptide there is no excuse for not having run one.
Counterion identity with net peptide content, given the 29 percent correction described above. A supplier quoting only a purity percentage has left out the number that changes the molarity most.
The chromatographic method, because a default peptide gradient does not retain a dipeptide well and a purity figure obtained that way measures very little.
Stereochemical confirmation, or at minimum a statement of which enantiomers were used in synthesis.
Sequence stated explicitly as Lys-Glu rather than only as a trade name, since several bioregulators in this family differ by a single residue and trade names carry no information about what is inside.
A closing note on the family relationships. Vilon at two residues, Vesugen at three and Livagen at four differ by single residues and share the Lys-Glu opening.
That progression looks deliberate rather than coincidental, and it suggests the programme was exploring how much sequence is needed for tissue specificity rather than designing each compound independently.
Nobody appears to have published a systematic comparison across the series at matched molar concentrations, which is an obvious and cheap experiment that the low material cost makes entirely practical.
Running it would either support the tissue-specificity claim or constrain it sharply, and either outcome would be worth more to the field than another single-compound study.
One last practical note. Because the compound is so cheap and so stable, it is unusually well suited to the kind of methodical control work that peptide research often skips for cost reasons.
A full reversed-sequence arm, free amino acid arms and a six-point concentration series can all be run from a single vial without the material budget ever entering the discussion.
That combination of low cost and high stability is rare enough in this catalogue to be worth naming as an advantage in its own right.
Few compounds in this range let a laboratory run the complete control set without a budget conversation first, and that is worth as much as any ranking figure on this page.
Published Literature
References verified against the publisher record. This literature originates almost entirely from one research programme, which bears directly on how it should be weighted.
- Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel; 2005.
- Khavinson VK. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144.
- Anisimov VN, Khavinson VK. Critical Reviews in Oncology/Hematology. 2010;74(1):46-66.
- Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Biochemistry (Moscow). 2011;76(11):1210-1219.
- Khavinson VK, Solovyov AY, Zhilinsky DV, Shataeva LK, Bandaletova TY. Bulletin of Experimental Biology and Medicine. 2012;153(4):500-505.
Frequently Asked Questions
What is Vilon peptide?
A lyophilized vial of the dipeptide Lys-Glu, written KE, the shortest compound in the Khavinson bioregulator range. Laboratory research use only, with no approved formulation in any jurisdiction.
What Vilon peptide dosage appears in the literature?
Rodent studies have used intraperitoneal and subcutaneous amounts of roughly 0.1 to 10 micrograms per kilogram. Russian clinical literature describes tens to low hundreds of micrograms per exposure over courses of ten to twenty days.
Why are those amounts so low?
They sit two to three orders of magnitude below where most short peptides in this catalogue are studied. That is a claim about potency which the proposed mechanism does not currently explain, and it is worth treating as a question rather than a fact.
Why is a two-residue peptide unusual?
Because it has one peptide bond, essentially no conformational preference, and a surface area smaller than most small-molecule drugs. There is very little of it for anything to recognise specifically.
How does the proposed mechanism handle that?
By sidestepping receptors entirely. The literature proposes a sequence-specific interaction with DNA that modulates transcription of tissue-associated genes, rather than a conventional receptor binding event.
Is that proposal harder for a dipeptide?
Considerably. Sequence-specific DNA recognition normally requires reading several base pairs, and a two-residue ligand offers minimal information content to do it with. The constraints are tightest here of anywhere in the family.
Why does counterion matter so much for Vilon?
Because at roughly 275.3 daltons, a single trifluoroacetate at 114 daltons is over 29 percent of the associated mass. That is the largest counterion correction of any compound in this catalogue.
What is the strongest specificity control?
The reversed sequence, Glu-Lys. It has identical composition and mass, differing only in order. With two residues there is exactly one alternative ordering, which makes the control unusually complete compared with a scrambled tetrapeptide.
Why run free amino acid arms?
To distinguish an effect of the intact dipeptide from an effect of lysine and glutamate separately after hydrolysis. At the same molar concentrations those arms separate the two possibilities directly.
How stable is the compound?
Among the most stable in the catalogue. No cysteine, no methionine, no tryptophan and no asparagine-glycine motif, so the usual degradation routes are all unavailable. Refrigerated storage is sufficient.
What should a supplier state?
Measured mass, counterion identity with net peptide content, the chromatographic method used, stereochemical confirmation, and the sequence explicitly as Lys-Glu rather than only a trade name.
Compliance Statement
Vilon peptide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its proposed mechanism has not been independently established, and amounts cited on this page are figures from published studies in the species those studies used. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
19 reviews for Vilon Peptide 20mg